Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. [electronic resource]
Producer: 20110307Description: 3503-6 p. digitalISSN:- 1873-2623
- Adult
- Alemtuzumab
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm -- administration & dosage
- Antilymphocyte Serum
- Biomarkers -- blood
- Biopsy
- Chi-Square Distribution
- Creatinine -- blood
- Daclizumab
- Drug Therapy, Combination
- Female
- Florida
- Graft Rejection -- immunology
- Humans
- Immunoglobulin G -- administration & dosage
- Immunosuppressive Agents -- administration & dosage
- Kaplan-Meier Estimate
- Kidney Function Tests
- Kidney Transplantation -- adverse effects
- Male
- Middle Aged
- Mycophenolic Acid -- administration & dosage
- Prospective Studies
- Risk Assessment
- Risk Factors
- Steroids -- administration & dosage
- Tacrolimus -- administration & dosage
- Time Factors
- Transplantation, Homologous
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.